View this email in your browser ([link removed])
[link removed] April 14, 2026


** Roundup: The latest resources powering HIV & STI advocacy
------------------------------------------------------------

Dear Advocate,

Advocates are driving progress in HIV and STI prevention—guiding research, expanding access, holding powerful actors accountable and elevating community priorities. This roundup highlights advocacy in action, from new resources and policy frameworks to updates on the rollout of the latest prevention tools.
TRACK
[link removed]


** Lenacapavir Access—What’s the Latest?
------------------------------------------------------------

Efforts are ramping up to roll out injectable LEN for PrEP ([link removed]) amid new questions about pricing, volumes and supply timelines. LEN delivery is underway in Eswatini, Kenya, Lesotho, Nigeria, Zambia and Zimbabwe, and initial supply has entered Mozambique, South Africa and Uganda. AVAC, Access Bridge ([link removed]) and the Coalition to Accelerate Access to Long-Acting PrEP ([link removed]) are tracking the progress and facilitating a coordinated introduction ([link removed]) .

At the same time, Médecins Sans Frontières (MSF) issued an open letter to Gilead Sciences, criticizing its refusal to sell LEN directly for use in MSF’s programs. The issue comes amid limited public information, as concerns mount ([link removed]) that constraining LEN access to limited procurement channels and timelines risks slowing its uptake and excluding populations outside of government-led programs.

AVAC developed this summary of key information ([link removed]) related to LEN to help drive transparency from all stakeholders and, hopefully, to accelerate the speed, scale and equity in its introduction.

Close watchers expect a further update today — April 14 at 9:00AM EDT — when leaders from the US Department of State, Gilead Sciences and the Global Fund participate in a discussion on “the LEN partnership and the evolution of US foreign assistance ([link removed]) ” at the Center for Strategic and International Studies (CSIS). Register here ([link removed]) to watch the live webcast.
AVAC's LEN Advocacy Resources ([link removed])
EXPLORE
[link removed]

AVAC and partners launched three new national advocacy agendas ([link removed]) on sexually transmitted infections (STIs) for Kenya, South Africa and Zimbabwe, to elevate STIs as national health priorities and accelerate actions on R&D and delivery of STI vaccines, diagnostics, prevention and care. “Each agenda reflects country-specific priorities, but, collectively, they elevate community voices, strengthen policy engagement and build regional momentum to ensure STI prevention, diagnosis and care receive the sustained attention they deserve,” said Alison Footman, PhD, senior program manager of STIs at AVAC. Join us for a webinar ([link removed]) May 12 to learn more.
EXPLORE THE ADVOCACY AGENDAS ([link removed])
READ
[link removed]


** Closing the Evidence Gap for Pregnant and Lactating People
------------------------------------------------------------

Pregnant and lactating people (PLP) have historically been excluded from biomedical research, leaving critical gaps in evidence and access to prevention tools. Building on global efforts, AVAC, the Pregnancy and HIV/AIDS: Seeking Equitable Study (PHASES) Project and a diverse group of stakeholders developed a clear action plan ([link removed]) to help close this gap. Advancing Ethical Biomedical HIV Prevention Research for Pregnant and Lactating People, an article published in the journal AIDS ([link removed]) , describes this effort and the essential role of communities in driving progress.
Read the Article ([link removed])
[link removed]
READ


** Global Prevention Coalition Releases New Global Access Framework for Country-Led Responses
------------------------------------------------------------

The Global HIV Prevention Coalition (GPC) launched a new 2030 Global Access Framework outlining how, by 2030, countries can ensure that 90% of people in need of HIV prevention services have access and that 90% of people living with HIV are virally suppressed. This, in combination, would lead to a 90% reduction in new HIV infections globally. “Innovations, especially lenacapavir, have added to the array of prevention choices. History will judge us harshly if we as a global community fail to meet this scientific moment," said Mitchell Warren, GPC Co-Chair on a recent webinar. ([link removed])
Read the Global Access Framework ([link removed])
WATCH
[link removed]


** The Choice Agenda Webinar: The Injectors of Tomorrow are Here Today
------------------------------------------------------------

Expanding PrEP access means meeting people where they are. The latest Choice Agenda webinar explored how community health workers and pharmacists are taking injectable PrEP beyond clinics and into homes, streets and communities. The Choice Agenda offers monthly webinars and a moderated listserv for advocacy on the latest in HIV prevention research – join the conversation here ([link removed]) .
Watch the Recording ([link removed])

Best,

AVAC
Follow us @hivpxresearch ([link removed])
[link removed] [link removed] [link removed]
Share this issue ([link removed])
AVAC Global Advocacy for HIV Prevention
+1 212 796 6423 [email protected] (mailto:[email protected]) www.avac.org ([link removed])
You're receiving this because you signed up for our newsletter. Not interested any longer?
Manage email preferences ([link removed]) | Unsubscribe ([link removed])